EG00229 (EG-00229) is a novel and potent Neuropilin 1 (NRP1) receptor antagonist with anticancer activity. It acts by selectively inhibiting VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2. EG00229 inhibits VEGFA binding to NRP1.

纯度：≥98%

CAS：1018927-63-3